Wedbush Reaffirms “Outperform” Rating for Artiva Biotherapeutics (NASDAQ:ARTV)
Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report)‘s stock had its “outperform” rating reaffirmed by equities researchers at Wedbush in a note issued to investors on Tuesday,Benzinga reports. They currently have a $18.00 price objective on the stock. Wedbush’s target price would indicate a potential upside of 394.51% from the company’s previous close. A number of […]
Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report)‘s stock had its “outperform” rating reaffirmed by equities researchers at Wedbush in a note issued to investors on Tuesday,Benzinga reports. They currently have a $18.00 price objective on the stock. Wedbush’s target price would indicate a potential upside of 394.51% from the company’s previous close. A number of […]
